S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION. (23rd June 2022) - Jain, N.; Thompson, P.; Burger, J.; Ferrajoli, A.; Takahashi, K.; Estrov, Z.; Borthakur, G.; Bose, P.; Kadia, T.; Pemmaraju, N.; Sasaki, K.; Konopleva, M.; et al.